INOVIO to Participate in Upcoming Scientific Conferences

Trending...
~ Inovio, a biotechnology company focused on developing and commercializing DNA medicines, has announced that it will be presenting data at several upcoming scientific conferences. These presentations will highlight key aspects of their lead product candidate, INO-3107, for the treatment of recurrent respiratory papillomatosis (RRP).

The company has also begun the rolling submission of its Biologics License Application (BLA) for INO-3107 and anticipates completing this process in the second half of 2025. Their goal is to have the application accepted by the U.S. Food and Drug Administration by the end of 2025.

In addition to showcasing their lead product candidate, Inovio will also be highlighting their next-generation DNA-medicine technology at these conferences. This includes presentations on a Phase 1 clinical trial of a DNA-encoded monoclonal antibody (DMAb) product candidate and new preclinical data on DPROTs addressing Hemophilia A.

The presentations on INO-3107 for RRP will take place at various conferences around the world. These include the American Academy of Otolaryngology – Head and Neck Surgery Annual Meeting in Indianapolis from October 11-13, where Inovio will present a poster titled "DNA Immunotherapy (INO-3107) Demonstrates a Durable Response for Treatment of HPV-6/11 Recurrent Respiratory Papillomatosis."

More on indianastop.com
At the World Vaccine Congress Europe in Amsterdam on October 13, Inovio's presentation titled "Leveraging the Potential of DNA Immunotherapy: Long-Term Efficacy in HPV-6 & 11 Recurrent Respiratory Papillomatosis" will take place at 3:45 PM CEST.

On October 19, at the European Society For Medical Oncology Congress in Berlin, Inovio will present a poster titled "DNA Immunotherapy (INO-3107) in HPV-6 & 11 Recurrent Respiratory Papillomatosis – Long-Term Efficacy."

The 37th Annual International Papillomavirus Society Conference in Bangkok on October 24 will feature a presentation by Inovio titled "Clinical Response to INO-3107 in RRP is Irrespective of Papilloma Microenvironment and Molecular Subtype" at 2:40 - 2:55 PM ICT. The following day, on October 25, an e-poster titled "DNA Immunotherapy (INO-3107) Induces Persistent Immune Responses Resulting in Long-term Efficacy Through Post-Treatment Year 2 for HPV 6&11 RRP" will be presented at 6:54 - 7:00 PM ICT.

At the International Society for Vaccines Annual Congress in Stellenbosch, South Africa on October 30, Inovio will present "Immunotherapy, INO-3107, is Well-Tolerated, Effective, and Elicits an Antigen-Specific T-cell Response in Adults with HPV-6 & 11 Recurrent Respiratory Papillomatosis" at 10:20 - 10:35 AM SAST.

More on indianastop.com
In addition to these presentations on INO-3107 for RRP, Inovio will also be showcasing their next-generation DNA medicine technology at various conferences. These include the European Society of Gene and Cell Therapy Congress in Seville from October 7-10 where they will present a poster titled "Employment of the CELLECTRA® in vivo gene delivery platform in a first in human (FIH) DNA encoded monoclonal antibody (DMAb) clinical trial."

At the World Vaccine Congress Europe on October 16, Inovio's presentation titled "DMAb Technology: Next Generation DNA Medicine Design and Delivery" will take place at 1:00 PM CET. On October 29, at the World Orphan Drug Congress in Amsterdam, their presentation titled "DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease" will take place at 11:10 AM CET.

Lastly, at the 14th World Federation of Hemophilia Global Forum in Montreal on November 14, Inovio will present "Novel FVIII Secretion Via Non-Viral Vector DNA Medicine Platform" at 1:45 PM EST.

Abstracts for these presentations will be made available on Inovio's website following the conferences.
Show All News | Report Violation

0 Comments

Latest on indianastop.com